Furthermore, we performed an experimental study to evaluate: a) the serum levels of GP73 in a cohort of biopsy-confirmed MASLD patients, and b) the diagnostic accuracy of GP73 to discriminate patients with MASH and significant or advanced fibrosis. Here, GOLM1 is linked to metabolic dysfunction-associated steatotic liver disease.